First-in-human phase I study exploring three schedules of OSI-027, a novel small molecule TORC1/TORC2 inhibitor, in patients with advanced solid tumors and lymphoma. A phase I study of the oral mTOR ...

A large, multi-institution study led by a Brown University physician-scientist could have important implications for the development of new classes of cancer therapeutics.

Cytotoxic T lymphocytes play a crucial role in adaptive immunity, primarily defending against tumors and viruses. These cells develop within the thymus gland and undergo rapid activation upon ...

Aging-US Issue 1 Volume 13 features "PAM (PIK3/AKT/mTOR) signaling in glia: potential contributions to brain tumors in aging" which reported that despite a growing proportion of aged individuals at ...